Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

INT230-6 Induced T-Cell Receptor Signaling, Macrophage Markers, and IL-18 and B-Cell Receptor Signaling Data Was Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2023 WESTPORT, Conn., June 6, 2023 /PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity”), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based … Read more

Intensity Therapeutics’ INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered Cytotoxic Treatment Leading to a Systemic Immune Response in Hot or Cold Tumors, Is A New Way To Treat Sarcoma Results to be Presented Today, June 3, at the 2023 … Read more